{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T19:39:23Z","timestamp":1772653163725,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Calcitonin gene-related peptide (CGRP) activation could play a causal role in the pathophysiology of chronic rhinosinusitis (CRS), a long-term inflammatory disease of the nasal cavity and paranasal sinuses. This study investigated the efficacy and safety of rimegepant 75 mg orally disintegrating tablet, a CGRP receptor antagonist, versus placebo for acute treatment of CRS. This double-blind, randomized, placebo-controlled, phase 2\/3 trial enrolled adults with CRS in the United States. Participants were randomized 1:1 to rimegepant or placebo stratified by the presence or absence of nasal polyps. Participants were dispensed a single dose of study drug administered when they experienced a qualifying facial pain\/pressure\/fullness (Numeric Rating Scale [NRS] \u22656). The primary efficacy endpoint was a change from baseline [CFB] at 2 hours post dose in the intensity of facial pain\/pressure\/fullness) with baseline NRS score \u22656. Secondary endpoints included a CFB at 2 hours post dose in the NRS score for nasal obstruction\/congestion and nasal discharge, and Total Nasal Symptom Score (TNSS); proportion of participants reporting headache pain relief at 2 hours post dose; and proportion of participants using rescue medication within 24 hours post dose. Efficacy outcomes were evaluated using a linear model. Of 261 participants (mean age: 49.3 years) randomized to rimegepant (n\u2009=\u2009131) or placebo (n\u2009=\u2009130), 96 and 100 had evaluable data for efficacy analyses. No significant treatment differences (P\u2009&gt;\u20090.05) were observed between groups for the primary (CFB at 2 hours post dose in the NRS score for intensity of facial pain\/pressure\/fullness, least-squares mean difference [95% CI] \u22120.1 [\u22120.7, 0.5]) and secondary outcomes. There were no serious safety findings. To our knowledge, this study is the first to explore the use of CGRP receptor antagonists for CRS. Although no treatment differences were identified, the findings could contribute to the design of future clinical trials and better disease understanding.<\/jats:p>\n                  <jats:p>Trial registration<\/jats:p>\n                  <jats:p>\n                    ClinicalTrials.gov\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05248997\" xlink:type=\"simple\">NCT05248997<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0342907","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:34:20Z","timestamp":1772649260000},"page":"e0342907","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of rimegepant 75 mg orally disintegrating tablet for the acute treatment of chronic rhinosinusitis in adults: Results from a multicenter, randomized, placebo-controlled, phase 2\/3 trial"],"prefix":"10.1371","volume":"21","author":[{"given":"Daniel","family":"Franjic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2932-0115","authenticated-orcid":true,"given":"Catherine","family":"Nalpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budhaditya","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Fullerton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"4","key":"pone.0342907.ref001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaci.2011.08.004","article-title":"Chronic rhinosinusitis: epidemiology and medical management","volume":"128","author":"DL Hamilos","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"pone.0342907.ref002","first-page":"500","article-title":"Chronic rhinosinusitis","volume":"96","author":"AR Sedaghat","year":"2017","journal-title":"Am Fam Physician"},{"issue":"6","key":"pone.0342907.ref003","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaip.2022.01.016","article-title":"Epidemiology of chronic rhinosinusitis: prevalence and risk factors","volume":"10","author":"AR Sedaghat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"pone.0342907.ref004","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaci.2018.12.986","article-title":"Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology","volume":"143","author":"D Dietz de Loos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0342907.ref005","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"WJ Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"1","key":"pone.0342907.ref006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/cea.14592","article-title":"Global incidence and prevalence of chronic rhinosinusitis: a systematic review","volume":"55","author":"HK Min","year":"2025","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"pone.0342907.ref007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1513\/pats.201003-028RN","article-title":"Treatment options for chronic rhinosinusitis","volume":"8","author":"JD Suh","year":"2011","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"pone.0342907.ref008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11908-011-0166-z","article-title":"Chronic rhinosinusitis as a multifactorial inflammatory disorder","volume":"13","author":"S Lee","year":"2011","journal-title":"Curr Infect Dis Rep"},{"key":"pone.0342907.ref009","article-title":"Clinical practice guideline (update): adult sinusitis","volume":"152","author":"RM Rosenfeld","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"pone.0342907.ref010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"RR Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"pone.0342907.ref011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12950-016-0121-8","article-title":"Pathogenesis of eosinophilic chronic rhinosinusitis","volume":"13","author":"SA Shah","year":"2016","journal-title":"J Inflamm (Lond)"},{"issue":"6","key":"pone.0342907.ref012","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","article-title":"Biotherapeutics in chronic rhinosinusitis with and without nasal polyps","volume":"5","author":"C Bachert","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"pone.0342907.ref013","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0194599810391852","article-title":"Cost burden of chronic rhinosinusitis: a claims-based study","volume":"144","author":"N Bhattacharyya","year":"2011","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"pone.0342907.ref014","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/BF00917475","article-title":"Mediation of prolonged increases in nasal mucosal blood flow by calcitonin gene-related peptide (CGRP)","volume":"10","author":"SP Rangi","year":"1990","journal-title":"J Clin Immunol"},{"key":"pone.0342907.ref015","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0091-6749(05)80226-X","article-title":"Neuropeptides and nasal secretion","volume":"86","author":"JN Baraniuk","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0342907.ref016","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3342\/kjorl-hns.2021.00934","article-title":"Expression and role of calcitonin gene-related peptide in patients with chronic rhinosinusitis with nasal polyposis","volume":"65","author":"J Chung","year":"2022","journal-title":"Korean J Otorhinolaryngol-Head Neck Surg"},{"key":"pone.0342907.ref017","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4414\/smw.2003.10262","article-title":"Chronic rhinosinusitis and neuropeptides","volume":"133","author":"JS Lacroix","year":"2003","journal-title":"Swiss Med Wkly"},{"key":"pone.0342907.ref018","author":"Pfizer","year":"2020"},{"key":"pone.0342907.ref019","author":"European Medicines Agency","year":"2022"},{"issue":"11","key":"pone.0342907.ref020","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/alr.23002","article-title":"CRS-PRO and SNOT-22 correlations with type 2 inflammatory mediators in chronic rhinosinusitis","volume":"12","author":"SD Racette","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"pone.0342907.ref021","doi-asserted-by":"crossref","first-page":"103879","DOI":"10.1016\/j.amjoto.2023.103879","article-title":"Using the sino-nasal outcome test (SNOT-22) to study outcome of treatment of nasal obstruction","volume":"44","author":"J Behnke","year":"2023","journal-title":"Am J Otolaryngol"},{"issue":"4","key":"pone.0342907.ref022","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaip.2023.12.016","article-title":"Efficacy of EDS-FLU for chronic rhinosinusitis: two randomized controlled trials (ReOpen1 and ReOpen2)","volume":"12","author":"JN Palmer","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"pone.0342907.ref023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2009.01.258","article-title":"Patient global impression of change scores within the context of a chronic pain rehabilitation program","volume":"10","author":"L Ferguson","year":"2009","journal-title":"J Pain"},{"issue":"12","key":"pone.0342907.ref024","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"K Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"2","key":"pone.0342907.ref025","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial","volume":"34","author":"R Marcus","year":"2014","journal-title":"Cephalalgia"},{"key":"pone.0342907.ref026","article-title":"Efficacy and safety of two rimegepant dosing regimens for the prevention of episodic migraine: a double-blind, placebo-controlled study. Abstracts from the 22nd International Headache Congress, 11-13 September 2025, S\u00e3o Paulo, Brazil","volume":"45","author":"PJTC Goadsby","year":"2025","journal-title":"Cephalalgia"},{"issue":"3","key":"pone.0342907.ref027","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/alr.23302","article-title":"The placebo effect in randomized-controlled trials of medical treatments for chronic rhinosinusitis: a systematic review and meta-analysis","volume":"14","author":"RM Pipaliya","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"issue":"12","key":"pone.0342907.ref028","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/alr.22028","article-title":"Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis","volume":"7","author":"NI Chowdhury","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"pone.0342907.ref029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejpain.2003.09.004","article-title":"Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale","volume":"8","author":"F Salaffi","year":"2004","journal-title":"Eur J Pain"},{"issue":"6","key":"pone.0342907.ref030","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.jaci.2015.10.012","article-title":"Patient-reported outcome measures for adult chronic rhinosinusitis: a systematic review and quality assessment","volume":"136","author":"L Rudmik","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"pone.0342907.ref031","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1016\/j.jaip.2024.06.049","article-title":"Patient-reported outcome measures in rhinitis and chronic rhinosinusitis","volume":"12","author":"MS Dykewicz","year":"2024","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:34:26Z","timestamp":1772649266000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342907"}},"subtitle":[],"editor":[{"given":"Dhammika Leshan","family":"Wannigama","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342907","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}